Table 1.
Occurrence of any prostate cancer and clinically significant prostate cancer in MRI-fusion guided biopsy targets stratified by PI-RADS score and year of biopsy.
| 2015-2017 | 2018-2021 | All | |||||||
|---|---|---|---|---|---|---|---|---|---|
| PI-RADS | Lesions | PCa (%) | CSC (%) | Lesions | PCa (%) | CSC (%) | Lesions | PCa (%) | CSC (%) |
| 1 | 7 | 2 (29) | 1 (14) | 2 | 0 (0) | 0 (0) | 9 | 2 (22) | 1 (11) |
| 2 | 55 | 10 (18) | 5 (9) | 16 | 3 (19) | 2 (13) | 71 | 13 (18) | 7 (10) |
| 3 | 53 | 15 (28) | 5 (9) | 55 | 12 (22) | 6 (11) | 108 | 27 (25) | 11 (10) |
| 4 | 23 | 16 (70) | 14 (61) | 66 | 24 (36) | 17 (26) | 89 | 40 (45) | 31 (35) |
| 5 | 23 | 16 (70) | 12 (52) | 24 | 13 (54) | 11 (46) | 47 | 29 (62) | 23 (49) |
PCa, prostate cancer; CSC, clinically significant prostate cancer.